EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

External validation of the Fetal Medicine Foundation model for preterm pre‐eclampsia prediction at 11–14 weeks in an Australian population

Sofonyas Abebaw Tiruneh iD, Daniel Lorber Rolnik iD, Roshan Selvaratnam, Fabricio da Silva Costa, Andrew McLennan, Jon Hyett iD, Helena Teede iD, Joanne Enticott iD

Acta Obstetricia et Gynecologica Scandinavica · 2025

DOI: 10.1111/aogs.70002 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Acta Obstetricia et Gynecologica Scandinavica, 2025. Verfasst von Sofonyas Abebaw Tiruneh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Monash Centre for Health Research and Implementation, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Pre-Eclampsia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Pre‐eclampsia causes adverse maternal and perinatal complications and is preventable through early screening and aspirin treatment. This study evaluates the predictive performance of the Fetal Medicine Foundation first‐trimester preterm pre‐eclampsia competing risks model in an Australian population. Material and Methods This was a retrospective cohort study of prospectively collected multisite screening data and pregnancy outcomes between 2014 and 2017 in Australia. Individualized risk for preterm pre‐eclampsia was calculated using the Fetal Medicine Foundation model at 11–14 weeks by using maternal factors, biophysical biomarkers (mean arterial pressure (MAP), uterine artery pulsatility index (UtA‐PI)), and serum biochemical biomarkers (placental growth factor (PlGF) and/or pregnancy‐associated plasma protein A (PAPP‐A)). The predictive performance was evaluated using the area under the receiver‐operating characteristic curve (AUC) and calibration. The detection rates for delivery with preterm pre‐eclampsia were calculated at a 10% fixed false‐positive rate. Decision curve analysis of the model was evaluated.

Results

Of 29 609 women screened, 132 (0.45%) experienced preterm pre‐eclampsia. The median age (interquartile range) was 34 (30–38) years. Women with pre‐eclampsia had higher multiple of the median values of MAP and UtA‐PI and lower values of PIGF and PAPP‐A compared to those without pre‐eclampsia. Combined screening by maternal factors, biophysical, and biochemical biomarkers yielded an AUC of 0.87 (95% CI 0.79–0.92), detecting 71% of preterm pre‐eclampsia cases at 10% fixed false‐positive rate, with the addition of PlGF improving the detection rate by 31% over sole PAPP‐A use. Preterm pre‐eclampsia screening using maternal factors with all biomarkers showed better clinical net benefit at preference thresholds between 1% and 12% compared to default strategies.

Conclusions

The Fetal Medicine Foundation model, combining maternal factors with biophysical and biochemical biomarkers, demonstrated similar predictive performance in the Australian population compared to previous validation studies in other settings, detecting 71% of preterm pre‐eclampsia cases at 10% fixed false‐positive rate. The clinical utility analysis showed that early screening and intervention strategies based on a risk‐based screening approach is more beneficial than universal or no intervention strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaHumansFemalePregnancyAdultPregnancy Trimester, FirstAustraliaRetrospective StudiesBiomarkersPlacenta Growth FactorPregnancy-Associated Plasma Protein-ARisk AssessmentUterine ArteryPredictive Value of Tests

Stichwörter der Autor:innen

Fetal Medicine Foundationmean arterial pressureplacental growth factorpredictionpregnancy‐associated plasma protein apre‐eclampsiauterine artery Pulsatility index

Substanzen

BiomarkersPlacenta Growth FactorPregnancy-Associated Plasma Protein-APGF protein, human

Autor:innen und Institutionen

  • Monash Centre for Health Research and Implementation, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia.
  • Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia.
  • Department of Obstetrics and Gynaecology, Monash University, Monash Health, Clayton, Victoria, Australia.
  • Maternal Fetal Medicine Unit, Gold Coast University Hospital and School of Medicine and Dentistry, Griffith University, Gold Coast, Queensland, Australia.
  • Sydney Ultrasound for Women, Sydney, New South Wales, Australia.
  • Discipline of Obstetrics, Gynaecology and Neonatology, The University of Sydney, Camperdown, New South Wales, Australia.

ORCID-Profile: Sofonyas Abebaw Tiruneh, Daniel Lorber Rolnik, Jon Hyett, Helena Teede, Joanne Enticott

Zitieren

APA

Tiruneh, S. A., Rolnik, D. L., Selvaratnam, R., da Silva Costa, F., McLennan, A., Hyett, J., Teede, H., & Enticott, J. (2025). External validation of the Fetal Medicine Foundation model for preterm pre‐eclampsia prediction at 11–14 weeks in an Australian population. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70002

Vancouver

Tiruneh SA, Rolnik DL, Selvaratnam R, da Silva Costa F, McLennan A, Hyett J, et al. External validation of the Fetal Medicine Foundation model for preterm pre‐eclampsia prediction at 11–14 weeks in an Australian population. Acta Obstetricia et Gynecologica Scandinavica. 2025. doi:10.1111/aogs.70002

BibTeX
@article{Tiruneh2025,
  author = {Tiruneh, Sofonyas Abebaw and Rolnik, Daniel Lorber and Selvaratnam, Roshan and da Silva Costa, Fabricio and McLennan, Andrew and Hyett, Jon and Teede, Helena and Enticott, Joanne},
  title = {External validation of the Fetal Medicine Foundation model for preterm pre‐eclampsia prediction at 11–14 weeks in an Australian population},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2025},
  doi = {10.1111/aogs.70002}
}
Kostenlos starten →